168 related articles for article (PubMed ID: 38381257)
1. Prognostic factors analysis of diffuse midline glioma.
Jiang J; Li WB; Xiao SW
J Neurooncol; 2024 Apr; 167(2):285-292. PubMed ID: 38381257
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
Dahlrot RH
Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors and survival study in high-grade glioma in the elderly.
Álvarez de Eulate-Beramendi S; Álvarez-Vega MA; Balbin M; Sanchez-Pitiot A; Vallina-Alvarez A; Martino-González J
Br J Neurosurg; 2016 Jun; 30(3):330-6. PubMed ID: 26828095
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Indicators for H3K27M-Mutant Diffuse Midline Glioma: A Population-Based Retrospective Surveillance, Epidemiology, and End Results Database Analysis.
Adhikari S; Bhutada AS; Ladner L; Cuoco JA; Entwistle JJ; Marvin EA; Rogers CM
World Neurosurg; 2023 Oct; 178():e113-e121. PubMed ID: 37423332
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and outcomes of elderly patients with diffuse gliomas: a multi-institutional cohort study by Kansai Molecular Diagnosis Network for CNS Tumors.
Sasaki T; Fukai J; Kodama Y; Hirose T; Okita Y; Moriuchi S; Nonaka M; Tsuyuguchi N; Terakawa Y; Uda T; Tomogane Y; Kinoshita M; Nishida N; Izumoto S; Nakajima Y; Arita H; Ishibashi K; Shofuda T; Kanematsu D; Yoshioka E; Mano M; Fujita K; Uematsu Y; Nakao N; Mori K; Kanemura Y
J Neurooncol; 2018 Nov; 140(2):329-339. PubMed ID: 30076584
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for pediatric, adolescent, and young adult patients with non-DIPG grade 4 gliomas: a contemporary pooled institutional experience.
Matsui JK; Allen PK; Perlow HK; Johnson JM; Paulino AC; McAleer MF; Fouladi M; Grosshans DR; Ghia AJ; Li J; Zaky WT; Chintagumpala MM; Palmer JD; McGovern SL
J Neurooncol; 2023 Jul; 163(3):717-726. PubMed ID: 37440097
[TBL] [Abstract][Full Text] [Related]
7. Re-resection for recurrent high-grade glioma in the setting of re-irradiation: more is not always better.
Palmer JD; Siglin J; Yamoah K; Dan T; Champ CE; Bar-Ad V; Werner-Wasik M; Evans JJ; Kim L; Glass J; Farrell C; Andrews DW; Shi W
J Neurooncol; 2015 Sep; 124(2):215-21. PubMed ID: 26024653
[TBL] [Abstract][Full Text] [Related]
8. Diffuse non-midline glioma with H3F3A K27M mutation: a prognostic and treatment dilemma.
López G; Oberheim Bush NA; Berger MS; Perry A; Solomon DA
Acta Neuropathol Commun; 2017 May; 5(1):38. PubMed ID: 28506301
[No Abstract] [Full Text] [Related]
9. The role of radiotherapy in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.
Ryken TC; Parney I; Buatti J; Kalkanis SN; Olson JJ
J Neurooncol; 2015 Dec; 125(3):551-83. PubMed ID: 26530266
[TBL] [Abstract][Full Text] [Related]
10. Clinical Characteristics and Prognostic Analysis of Glioma in Human Immunodeficiency Virus-Infected Patients.
Wang T; Gao T; Niu X; Xing X; Yang Y; Liu Y; Mao Q
World Neurosurg; 2018 Jun; 114():e218-e223. PubMed ID: 29524717
[TBL] [Abstract][Full Text] [Related]
11. Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy.
Park CK; Lee SH; Han JH; Kim CY; Kim DW; Paek SH; Kim DG; Heo DS; Kim IH; Jung HW
BMC Cancer; 2009 Dec; 9():450. PubMed ID: 20017960
[TBL] [Abstract][Full Text] [Related]
12. Impact of tumor location and pathological discordance on survival of children with midline high-grade gliomas treated on Children's Cancer Group high-grade glioma study CCG-945.
Eisenstat DD; Pollack IF; Demers A; Sapp MV; Lambert P; Weisfeld-Adams JD; Burger PC; Gilles F; Davis RL; Packer R; Boyett JM; Finlay JL
J Neurooncol; 2015 Feb; 121(3):573-81. PubMed ID: 25431150
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Baumert BG; Hegi ME; van den Bent MJ; von Deimling A; Gorlia T; Hoang-Xuan K; Brandes AA; Kantor G; Taphoorn MJB; Hassel MB; Hartmann C; Ryan G; Capper D; Kros JM; Kurscheid S; Wick W; Enting R; Reni M; Thiessen B; Dhermain F; Bromberg JE; Feuvret L; Reijneveld JC; Chinot O; Gijtenbeek JMM; Rossiter JP; Dif N; Balana C; Bravo-Marques J; Clement PM; Marosi C; Tzuk-Shina T; Nordal RA; Rees J; Lacombe D; Mason WP; Stupp R
Lancet Oncol; 2016 Nov; 17(11):1521-1532. PubMed ID: 27686946
[TBL] [Abstract][Full Text] [Related]
14. Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients.
Lote K; Egeland T; Hager B; Stenwig B; Skullerud K; Berg-Johnsen J; Storm-Mathisen I; Hirschberg H
J Clin Oncol; 1997 Sep; 15(9):3129-40. PubMed ID: 9294476
[TBL] [Abstract][Full Text] [Related]
15. Clinical features, management and outcomes of high-grade glioma patients in Ramathibodi Hospital.
Chansriwong P; Sirisinha T
J Med Assoc Thai; 2010 Feb; 93 Suppl 2():S68-73. PubMed ID: 21299082
[TBL] [Abstract][Full Text] [Related]
16. Diffuse midline glioma-H3K27M mutant. A novel entity with a defining and specific IHC marker.
Agarwal P; Aiyer HM
Indian J Pathol Microbiol; 2021; 64(2):351-353. PubMed ID: 33851633
[TBL] [Abstract][Full Text] [Related]
17. Differences in survival prognosticators between children and adults with H3K27M-mutant diffuse midline glioma.
Gong X; Kuang S; Deng D; Wu J; Zhang L; Liu C
CNS Neurosci Ther; 2023 Dec; 29(12):3863-3875. PubMed ID: 37311690
[TBL] [Abstract][Full Text] [Related]
18. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM
Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894
[TBL] [Abstract][Full Text] [Related]
19. Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial.
Rodriguez Gutierrez D; Jones C; Varlet P; Mackay A; Warren D; Warmuth-Metz M; Aliaga ES; Calmon R; Hargrave DR; Cañete A; Massimino M; Azizi AA; Le Deley MC; Saran F; Rousseau RF; Zahlmann G; Garcia J; Vassal G; Grill J; Morgan PS; Jaspan T
Clin Cancer Res; 2020 Apr; 26(8):1856-1865. PubMed ID: 31924736
[TBL] [Abstract][Full Text] [Related]
20. Extent of resection and molecular pathologic subtype are potent prognostic factors of adult WHO grade II glioma.
Choi J; Kim SH; Ahn SS; Choi HJ; Yoon HI; Cho JH; Roh TH; Kang SG; Chang JH; Suh CO
Sci Rep; 2020 Feb; 10(1):2086. PubMed ID: 32034238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
